JP2016508123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508123A5 JP2016508123A5 JP2015547046A JP2015547046A JP2016508123A5 JP 2016508123 A5 JP2016508123 A5 JP 2016508123A5 JP 2015547046 A JP2015547046 A JP 2015547046A JP 2015547046 A JP2015547046 A JP 2015547046A JP 2016508123 A5 JP2016508123 A5 JP 2016508123A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- serf2
- pharmaceutical composition
- composition according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 16
- 101000650652 Homo sapiens Small EDRK-rich factor 2 Proteins 0.000 claims 15
- 102100027692 Small EDRK-rich factor 2 Human genes 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 210000000130 stem cell Anatomy 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000002919 epithelial cell Anatomy 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 3
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000001608 connective tissue cell Anatomy 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 101710108846 Eukaryotic peptide chain release factor GTP-binding subunit Proteins 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000012866 low blood pressure Diseases 0.000 claims 1
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 210000004409 osteocyte Anatomy 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12197192.3A EP2742935A1 (en) | 2012-12-14 | 2012-12-14 | SERF2 for the treatment of atrophy and for increasing cell growth |
| EP12197192.3 | 2012-12-14 | ||
| PCT/EP2013/076547 WO2014090991A1 (en) | 2012-12-14 | 2013-12-13 | Medicament for atrophy treatment or increasing cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016508123A JP2016508123A (ja) | 2016-03-17 |
| JP2016508123A5 true JP2016508123A5 (enExample) | 2017-01-19 |
Family
ID=47355920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547046A Pending JP2016508123A (ja) | 2012-12-14 | 2013-12-13 | 萎縮治療のための又は細胞増殖を増加させるための医薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9637529B2 (enExample) |
| EP (2) | EP2742935A1 (enExample) |
| JP (1) | JP2016508123A (enExample) |
| CN (1) | CN105163726A (enExample) |
| AU (1) | AU2013357283A1 (enExample) |
| CA (1) | CA2895131A1 (enExample) |
| WO (1) | WO2014090991A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2553225C2 (ru) | 2008-05-23 | 2015-06-10 | Сива Корпорейшн | Способ облегчения регенерации |
| EP3194439B1 (en) | 2014-09-19 | 2022-01-19 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| HUE058854T2 (hu) | 2016-02-19 | 2022-09-28 | Siwa Corp | Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával |
| KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
| JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
| JP2020502078A (ja) * | 2016-11-30 | 2020-01-23 | パイアン・バイオテクノロジー・インコーポレイテッドＰａｅａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎｃ． | ミトコンドリアを含む医薬組成物 |
| CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| CN113337460A (zh) * | 2021-06-10 | 2021-09-03 | 呼和浩特职业学院 | 一种绵羊骨骼肌卫星细胞的高效分离和纯化方法 |
| CN118108828B (zh) * | 2022-11-29 | 2025-10-28 | 上海众启生物科技有限公司 | 含有serf2的蛋白抗原组合及其应用 |
| CN117538545B (zh) * | 2024-01-09 | 2024-07-05 | 上海众启生物科技有限公司 | 一种用于阿尔茨海默症检测的蛋白抗原组合及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2399776A1 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20070042392A1 (en) * | 2000-02-03 | 2007-02-22 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
-
2012
- 2012-12-14 EP EP12197192.3A patent/EP2742935A1/en not_active Withdrawn
-
2013
- 2013-12-13 EP EP13818997.2A patent/EP2931264A1/en not_active Withdrawn
- 2013-12-13 WO PCT/EP2013/076547 patent/WO2014090991A1/en not_active Ceased
- 2013-12-13 US US14/651,809 patent/US9637529B2/en not_active Expired - Fee Related
- 2013-12-13 CN CN201380072269.4A patent/CN105163726A/zh active Pending
- 2013-12-13 CA CA2895131A patent/CA2895131A1/en not_active Abandoned
- 2013-12-13 JP JP2015547046A patent/JP2016508123A/ja active Pending
- 2013-12-13 AU AU2013357283A patent/AU2013357283A1/en not_active Abandoned
-
2017
- 2017-03-31 US US15/475,418 patent/US20170253641A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508123A5 (enExample) | ||
| JP2012041342A5 (enExample) | ||
| Aujla et al. | TH17 cells in asthma and inflammation | |
| JP2011225596A5 (enExample) | ||
| JP2014526441A5 (enExample) | ||
| WO2012012347A3 (en) | Methods of intravenous administration of glyburide and other drugs | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| JP2011528333A5 (enExample) | ||
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| NZ603028A (en) | Tfpi inhibitors and methods of use | |
| JP2016516016A5 (enExample) | ||
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| RU2015154737A (ru) | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| NZ713295A (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| Wang et al. | Role of mesenchymal stem cells in sepsis and their therapeutic potential in sepsis-associated myopathy | |
| BR112015026286A2 (pt) | angiotensinas na distrofia muscular | |
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| JP2016510808A5 (enExample) | ||
| WO2021206833A3 (en) | Methods and compositions for treating tissue damage resulting from viral infections | |
| Kogelmann et al. | Case study of 8 patients with multiple organ failure treated additionally with CytoSorbents haemadsorption as adjunctive therapy in septic shock and severe SIRS in cardiac failure | |
| Michalek et al. | Stromal Vascular Fraction Cell Therapy for Idiopathic Pulmonary Fibrosis-Cure without Side Effects | |
| FENG et al. | Effects of different concentrations of dexmedetomidine on neuromuscular block induced by rocuronium | |
| WO2011106674A3 (en) | Use of endogenous antioxidant proteins in the treatment of stroke |